609 fundamentals
An in-depth look to ABIONYX PHARMA SA operating, investing, and financing activities
609 free cash flow for H2 23 is -1.2 M EUR. For 2023, 609 free cash flow was -3.8 M EUR and operating cash flow was -3.7 M EUR.
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
TTM